Eagle Capital Growth Fund, Inc. (GRF)
| Market Value | 40.27M |
| Revenue (ttm) | 996,733 +3.7% |
| Net Income | 5.03M -9.2% |
| EPS | 1.27 -9.2% |
| Shares Out | 3.97M |
| PE Ratio | 8.01 |
| Forward PE | n/a |
| Dividend | $0.85 (8.37%) |
| Ex-Dividend Date | Nov 21, 2025 |
| Volume | 455 |
| Open | 10.20 |
| Previous Close | 10.20 |
| Day's Range | 10.15 - 10.20 |
| 52-Week Range | 9.50 - 11.85 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GRF
Eagle Capital Growth Fund, Inc. is a closed-end equity mutual fund launched and managed by Sims Capital Management LLC. The fund invests in the public equity markets of the United States. It makes its investments in the stocks of companies operating across diversified sectors. The fund benchmarks the performance of its portfolio against the S&P 500 Index. It was previously known as NAIC Growth Fund, Inc. Eagle Capital Growth Fund, Inc. was formed on April 11, 1989 and is domiciled in the United States.
Financial Performance
In 2025, Eagle Capital Growth Fund's revenue was $996,733, an increase of 3.67% compared to the previous year's $961,494. Earnings were $5.03 million, a decrease of -9.25%.
Financial StatementsNews
Eagle Capital Growth Fund Earnings Call Transcript: Q1 2026
Q1 2026 delivered solid growth in Biopharma, led by immunoglobulins, and improved margins through plasma sourcing optimization and cost discipline. The balance sheet was strengthened via refinancing, and the company remains on track to meet 2026 guidance.
Eagle Capital Growth Fund Earnings Call Transcript: Q4 2025
Revenue and adjusted EBITDA grew strongly in 2025, with free cash flow and leverage targets exceeded. Strategic partnerships in Egypt and Canada, along with a focus on margin-accretive growth, position the company for continued deleveraging and profitability in 2026.
Eagle Capital Growth Fund Earnings Call Transcript: Q3 2025
Q3 2025 saw strong revenue and EBITDA growth, led by immunoglobulins and biopharma, with improved free cash flow and leverage. Guidance for 2025 is reaffirmed, despite FX and IRA headwinds, and the pipeline remains robust with key launches on track.
Eagle Capital Growth Fund Declares Year-End Distribution of $0.85 Per Share in Cash
MILWAUKEE--(BUSINESS WIRE)--The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.85 per share in cash. The record date for this distribution i...
Eagle Capital Growth Fund Earnings Call Transcript: Q2 2025
H1 2025 saw robust revenue and EBITDA growth, margin expansion, and strong Free Cash Flow, driven by Biopharma and Diagnostics. Leverage hit a five-year low, dividend payments resumed, and guidance for 2025 was reaffirmed despite FX and pricing pressures.
Eagle Capital Growth Fund Earnings Call Transcript: Q1 2025
Q1 2025 delivered record revenue, EBITDA, and free cash flow, with strong growth in biopharma and diagnostics. Guidance for 2025 is reaffirmed, supported by robust demand, operational efficiencies, and a resilient global supply chain, despite ongoing policy and macroeconomic uncertainties.
Eagle Capital Growth Fund Transcript: CMD 2025
Management outlined a five-year plan to reach €10 billion revenue by 2029 and €14 billion by 2034, driven by biopharma growth, innovation, and operational efficiency. Margin expansion, disciplined capital allocation, and new product launches underpin the strategy, with dividends to resume in 2025.
Eagle Capital Growth Fund Earnings Call Transcript: Q4 2024
Record revenues and adjusted EBITDA were achieved in 2024, driven by strong Biopharma growth, robust demand for immunoglobulin and albumin, and operational efficiencies. Free cash flow and deleveraging exceeded expectations, with no major CapEx needed in the near term.
Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash
MILWAUKEE--(BUSINESS WIRE)--The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.68 per share in cash.
Eagle Capital Growth Fund Earnings Call Transcript: Q3 2024
Q3 2024 saw double-digit revenue and EBITDA growth, improved free cash flow, and reduced leverage, driven by strong Biopharma and IG performance. Management remains confident in meeting full-year guidance, with continued focus on operational efficiency, innovation, and deleveraging.
Eagle Capital Growth Fund Earnings Call Transcript: Q2 2024
Revenue grew 7.5% year-over-year in H1, with strong BioPharma and albumin performance, and adjusted EBITDA up 22%. Debt reduction advanced via Shanghai RAAS divestment, and full-year guidance for revenue, EBITDA, and positive free cash flow is reaffirmed.
Eagle Capital Growth Fund Earnings Call Transcript: Q1 2024
Eagle Capital Growth Fund Earnings Call Transcript: Q4 2023
Eagle Capital Growth Fund Transcript: Status Update
Eagle Capital Growth Fund Earnings Call Transcript: Q3 2023
Eagle Capital Growth Fund Declares Year-End Distribution of $0.35 Per Share in Cash
MILWAUKEE--(BUSINESS WIRE)--The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.35 per share in cash. The record date for this distribution i...
Eagle Capital Growth Fund Earnings Call Transcript: Q2 2023
Eagle Capital Growth Fund Earnings Call Transcript: Q1 2023
Eagle Capital Growth Fund Earnings Call Transcript: Q4 2022
Eagle Capital Growth Fund Earnings Call Transcript: Q3 2022
Eagle Capital Growth Fund Declares Year-End Distribution of $0.37 Per Share in Cash
MILWAUKEE--(BUSINESS WIRE)--The Eagle Capital Growth Fund, Inc. ("Fund") (NYSE American: GRF) today declared a year-end distribution of $0.37 per share in cash.
Eagle Capital Growth Fund Earnings Call Transcript: Q2 2022
Eagle Capital Growth Fund Earnings Call Transcript: Q4 2021
Eagle Capital Growth Fund Declares Year-End Distribution of $0.97 Per Share
MILWAUKEE--(BUSINESS WIRE)--The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.97 per share in cash. The record date for this distribution i...